drugset / Trial / NCT00357084
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
Phase 2
Completed
53 enrolled
Fred Hutchinson Cancer Center
National Cancer Institute (NCI) · collab
Supportive care
Summary
RATIONALE: Methotrexate and glucocorticoid therapy, such as prednisone or methylprednisolone, may be an effective treatment for acute graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This phase II trial is studying how well giving methotrexate together with glucocorticoids works in treating patients with newly diagnosed acute graft-versus-host disease after donor stem cell transplant.
Timeline
- Start
- 2006-05
- Primary completion
- 2007-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methotrexate | Small molecule | — | Intravenous |
| Subject | Methylprednisolone | Other / unclassified | — | Intravenous |
| Subject | Prednisone | Other / unclassified | — | Intravenous |